Diabetes drug 'Actos' to be pulled from market because of risk of bladder cancer

Published: 2011-06-15 06:56:00

Updated: 2011-06-15 06:56:00

Japanese pharmaceutical company Takeda’s blockbuster anti-diabetes pill “Actos (pioglitazone)” faces being banned in the Korean market as the Korea Food and Drug Administration (KFDA) on Monday ordered doctors to refrain from prescribing it for type-2 diabetes patients due to bladder cancer risk....

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK